CCG
AZN icon

Cloverfields Capital Group’s AstraZeneca AZN Stock Holding History

Cloverfields Capital Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,857
Closed -$2.64M – 98
2025
Q2 		$2.64M Buy
18,857
+1,050
+6% +$147K 0.78% 55
2025
Q1 		$2.62M Sell
17,807
-60
-0.3% -$8.68K 0.86% 47
2024
Q4 		$2.34M Buy
17,867
+1,600
+10% +$224K 0.75% 48
2024
Q3 		$2.53M Sell
16,267
-2,750
-14% -$444K 0.82% 49
2024
Q2 		$2.97M Buy
19,017
+170
+0.9% +$25.6K 1% 45
2024
Q1 		$2.55M Buy
18,847
+213
+1% +$28.2K 0.86% 46
2023
Q4 		$2.51M Buy
18,634
+5,938
+47% +$772K 0.98% 43
2023
Q3 		$1.72M Hold
12,696
– – 0.77% 51
2023
Q2 		$1.82M Buy
12,696
+5,220
+70% +$768K 0.59% 51
2023
Q1 		$1.04M Buy
7,476
+3,454
+86% +$465K 0.31% 57
2022
Q4 		$545K Hold
4,022
– – 0.17% 52
2022
Q3 		$441K Hold
4,022
– – 0.15% 53
2022
Q2 		$531K Sell
4,022
-1,942
-33% -$255K 0.16% 50
2022
Q1 		$791K Sell
5,964
-659
-10% -$79K 0.25% 45
2021
Q4 		$772K Hold
6,623
– – 0.24% 47
2021
Q3 		$795K Buy
6,623
+31
+0.5% +$3.61K 0.26% 46
2021
Q2 		$790K Buy
6,592
+74
+1% +$8.12K 0.23% 45
2021
Q1 		$648K Buy
6,518
+138
+2% +$13.9K 0.21% 48
2020
Q4 		$638K Buy
+6,380
New +$676K 0.24% 45

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cloverfields Capital Group's AZN Position: Q3 2025 in Review

Cloverfields Capital Group sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 18,857 shares — an estimated $2.64M sold.

Cloverfields Capital Group first reported a position in AZN in Q4 2020 and held it in 19 quarters. The position peaked at $2.97M in Q2 2024. 1,288 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

  • Cloverfields Capital Group reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
  • Cloverfields Capital Group sold 18,857 AstraZeneca shares in Q3 2025, an estimated $2.64M.
  • Cloverfields Capital Group first reported a position in AstraZeneca in Q4 2020 and held it in 19 quarters.
  • Cloverfields Capital Group's AstraZeneca position peaked at $2.97M in Q2 2024.
  • 1,288 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Cloverfields Capital Group's 13F filing for Q3 2025, filed 13 Nov 2025.